Medicine and Dentistry
Patient
100%
Therapeutic Procedure
51%
Neoplasm
43%
Overall Survival
41%
Breast Cancer
29%
Inpatient
25%
Diseases
21%
Progression Free Survival
21%
Combination Therapy
18%
Metastatic Carcinoma
18%
Gastrointestinal Stromal Tumor
18%
Metastatic Breast Cancer
16%
Survival
16%
Surgery
13%
Hormone Therapy
11%
Palbociclib
11%
Liver
11%
Oncology
10%
Combined Therapy
10%
Bleeding
10%
Trastuzumab
10%
Colorectal Cancer
10%
Pertuzumab
9%
Non Small Cell Lung Cancer
9%
Metastasectomy
9%
Exon
9%
Analysis
9%
Toxicity
8%
Metastatic Colorectal Cancer
8%
Head and Neck Cancer
8%
Prospective Study
7%
Neoadjuvant Chemotherapy
7%
Malignant Neoplasm
7%
Receptor
7%
Mandible Resection
7%
Bone Necrosis
7%
Head and Neck Tumor
7%
Tooth Extraction
7%
Trastuzumab
7%
Abdominal Cancer
7%
Arm
7%
Imatinib
6%
Tyrosine-Kinase Inhibitor
6%
Multivariate Analysis
6%
Follow up
6%
Bevacizumab
6%
Pancreas Cancer
5%
Colorectal Liver Metastasis
5%
Cetuximab
5%
Diseases
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
30%
Overall Survival
22%
Progression Free Survival
14%
Pertuzumab
13%
Breast Cancer
13%
Survival
12%
Diseases
10%
Epidermal Growth Factor Receptor 2
8%
Overall Survival
7%
Colorectal Carcinoma
7%
Gamma Urogastrone
7%
Palbociclib
7%
Trastuzumab
7%
Progression Free Survival
7%
Toxicity
6%
Cisplatin
6%
Metastatic Breast Cancer
6%
Neoplasm
6%
Bevacizumab
5%
Cetuximab
5%
Taxane
5%
Metastatic Breast Cancer
5%
Everolimus
5%
Exemestane
5%
Clinical Trial
5%
